Cite
Coles AJ, Arnold DL, Bass AD, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021;14:1756286420982134doi: 10.1177/1756286420982134.
Coles, A. J., Arnold, D. L., Bass, A. D., Boster, A. L., Compston, D. A. S., Fernández, �. �., Havrdová, E. K., Nakamura, K., Traboulsee, A., Ziemssen, T., Jacobs, A., Margolin, D. H., Huang, X., Daizadeh, N., Chirieac, M. C., & Selmaj, K. W. (2021). Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic advances in neurological disorders, 141756286420982134. https://doi.org/10.1177/1756286420982134
Coles, Alasdair J, et al. "Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial." Therapeutic advances in neurological disorders vol. 14 (2021): 1756286420982134. doi: https://doi.org/10.1177/1756286420982134
Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fernández Ó, Havrdová EK, Nakamura K, Traboulsee A, Ziemssen T, Jacobs A, Margolin DH, Huang X, Daizadeh N, Chirieac MC, Selmaj KW. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134. doi: 10.1177/1756286420982134. eCollection 2021. PMID: 34035833; PMCID: PMC8072102.
Copy
Download .nbib